# CLL12 (NCT02863718)

> Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02863718
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: German CLL Study Group
- Conditions: Chronic Lymphocytic Leukemia
- Interventions: Ibrutinib; Placebo
- Enrollment: 515
- Primary outcome: Event-free survival (EFS)

## Commentary we found

- YouTube: 27
- Podcasts: 20
- X threads: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cll12-nct02863718

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02863718", "email": "<work email>"}; the inbox owner confirms by the emailed link.